Cardiometabolic

Omega-3

EPA · DHA

Packet question: triglycerides, cardiovascular outcomes, cognition, physical healthy aging, mortality and lifespanEvidence level C

Level C describes limited, mixed or context-dependent human evidence for this exact question; read the conclusion for direction and limits.

This C grade applies only to the controlling packet question across non-interchangeable interventions. Outcome grades below are more specific; it is not an ordinary-supplement, ingredient-wide or finished-product grade.

IN PLAIN LANGUAGE

Why people are interested

EPA and DHA become part of cell membranes and influence blood fats and signalling. The result depends strongly on the dose, source and person.

Outcome map

One ingredient. Different questions.

Evidence can be stronger for a specific marker or population and weaker for a broader promise. Each row answers a separate question.

01
Elevated triglycerides
Defined prescription-strength omega-3 products lower elevated triglycerides in specified populations; ordinary capsules are not interchangeable.
Evidence level A
02
Cardiovascular events
Cardiovascular results are mixed and depend on the exact product, dose, comparator and population studied.
Evidence level C
03
Ordinary retail supplements
Evidence from named prescription products does not establish that an ordinary retail supplement reproduces their clinical effects.
Evidence level D
04
Cognition and physical aging
Large trials do not establish that ordinary supplementation prevents dementia or preserves physical performance in relatively healthy older adults.
Evidence level D
05
Biological aging and lifespan
Human studies have not established slower biological aging, lower all-cause mortality or longer life from supplementation.
Evidence level D

Library trackFoundation topic

Last reviewed22 Aug 2026

Guide scopeIngredient research only

How it may work

Incorporates into cell membranes and influences lipid mediators and triglyceride metabolism.

What people have studied

Omega-3 is not one intervention: dietary fish, ordinary supplements and named prescription products answer different evidence questions. Defined prescription products lower triglycerides, but cardiovascular results differ by formulation and population; prescription evidence does not validate ordinary supplements, and healthy-aging or lifespan benefits are not established.

What to consider

High-dose use in higher-risk cardiovascular populations has an atrial-fibrillation signal. Pooled trials show no significant overall bleeding increase, while high-dose purified EPA shows a small absolute increase; source quality and oxidation remain finished-product questions.

Local pathway

Formula, source, dose and claims require local clearance.

Sources + indexes

See where the explanation comes from.

Open the linked research and official records behind this guide. Early topics may begin with a research index while stronger sources are added.